Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XOMA

XOMA Royalty Corp

Oct 23 • 04:00PM ET

34.27

+0.40 1.18 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD VRTX REGN BMRN BIIB IONS INCY NBIX EXEL

| Held by: VTI IWM VXF IWO VTWO IWN IWC VTWG RSSL DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.54	Insider Own	2.03%	Shs Outstand	12.06M	Perf Week	-6.08%
Market Cap	414.25M	Forward P/E	68.20	EPS next Y	0.50	Insider Trans	-63.73%	Shs Float	11.84M	Perf Month	-6.82%
Enterprise Value	464.96M	PEG	-	EPS next Q	-0.04	Inst Own	67.84%	Short Float	2.18%	Perf Quarter	32.68%
Income	-17.72M	P/S	9.22	EPS this Y	132.88%	Inst Trans	6.17%	Short Ratio	5.13	Perf Half Y	41.44%
Sales	44.95M	P/B	5.71	EPS next Y	-7.37%	ROA	-5.12%	Short Interest	0.26M	Perf YTD	30.40%
Book/sh	6.00	P/C	4.94	EPS next 5Y	-	ROE	-12.42%	52W High	39.92 -14.15%	Perf Year	20.41%
Cash/sh	6.94	P/FCF	-	EPS past 3/5Y	- -48.78%	ROIC	-9.09%	52W Low	18.35 86.74%	Perf 3Y	108.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-9.28% 9.17%	Gross Margin	96.85%	Volatility	5.21% 5.75%	Perf 5Y	61.42%
Dividend TTM	-	EV/Sales	10.34	EPS Y/Y TTM	38.01%	Oper. Margin	-47.52%	ATR (14)	2.01	Perf 10Y	66.36%
Dividend Ex-Date	-	Quick Ratio	4.88	Sales Y/Y TTM	194.98%	Profit Margin	-39.42%	RSI (14)	42.40	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	4.88	EPS Q/Q	-47.80%	SMA20	-6.86%	Beta	1.14	Target Price	69.67
Payout	-	Debt/Eq	1.24	Sales Q/Q	18.43%	SMA50	-4.07%	Rel Volume	0.73	Prev Close	33.87
Employees	13	LT Debt/Eq	1.11	Earnings	Aug 13 BMO	SMA200	25.49%	Avg Volume	50.42K	Price	34.27
IPO	Jun 06, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	393.33% 39.86%	Trades		Volume	36,403	Change	1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	The Benchmark Company	Buy	$35
Apr-29-24	Initiated	Leerink Partners	Outperform	$40
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral	$22
Jun-29-21	Initiated	Aegis Capital	Buy	$60
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$30 → $56
Jan-18-18	Reiterated	H.C. Wainwright	Buy	$38 → $49
Oct-17-17	Resumed	H.C. Wainwright	Buy	$38
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform	$9 → $19
Jun-12-17	Initiated	H.C. Wainwright	Buy	$15
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral	$17 → $14
Mar-11-16	Reiterated	Wedbush	Outperform	$6 → $3
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy	$9
Apr-29-14	Upgrade	MLV & Co	Hold → Buy	$7
Mar-11-14	Downgrade	MLV & Co	Buy → Hold	$8 → $7
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy	$6.50 → $10
Oct-31-13	Reiterated	MLV & Co	Buy	$7.50 → $8
May-09-13	Reiterated	Ladenburg Thalmann	Buy	$5 → $6

Show Previous Ratings

Oct-20-25 09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
Oct-17-25 11:45AM	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement (GlobeNewswire)
Oct-02-25 04:43PM	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Sep-24-25 06:00AM	ESSA Pharma Inc. Amends Agreement with XenoTherapeutics (PR Newswire)
Sep-23-25 02:00AM	Why Xoma, a drug royalty firm, is hunting biotech zombies (BioPharma Dive)
07:30AM	Loading…
Sep-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-19-25 09:55AM	Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect? (Zacks)
Sep-17-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. (GlobeNewswire)
Sep-03-25 09:55AM	Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know (Zacks)
07:30AM	XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-01-25 09:55AM	Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-20-25 12:52PM	Xoma, a drug royalty specialist, buys another zombie biotech (BioPharma Dive)
08:49AM	Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share (GlobeNewswire)
Aug-18-25 09:55AM	How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% (Zacks)
Aug-13-25 04:55PM	LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +8.54%
08:55AM	Loading…
08:55AM	XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:51AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-11-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics (GlobeNewswire)
Aug-07-25 05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-06-25 09:10AM	Novavax (NVAX) Q2 Earnings and Revenues Top Estimates (Zacks) -7.10%
Aug-04-25 08:15AM	Xoma strikes deals to buy struggling biotechs HilleVax, Lava (BioPharma Dive) +10.01%
07:30AM	XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right (GlobeNewswire)
07:00AM	HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right (GlobeNewswire)
Jul-14-25 08:00AM	ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction (PR Newswire)
Jul-10-25 04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jun-27-25 07:30AM	Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jun-24-25 10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks) +5.23%
Jun-18-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
May-27-25 08:01AM	XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million (GlobeNewswire)
08:50AM	Loading…
May-13-25 08:50AM	XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates (Zacks) +10.89%
07:48AM	XOMA Royalty: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements (GlobeNewswire)
May-07-25 07:30AM	XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire) +6.25%
Apr-22-25 04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-14-25 07:30AM	XOMA Royalty Completes Sale of Kinnate Pipeline Assets (GlobeNewswire)
Apr-09-25 09:45AM	XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey) +7.62%
Apr-08-25 07:15AM	BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 (ACCESSWIRE)
12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Apr-02-25 07:30AM	XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-20-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-17-25 04:30PM	XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements (GlobeNewswire)
Feb-24-25 04:05PM	XOMA Royalty to Present at Investor Conferences in March (GlobeNewswire)
Feb-04-25 07:30AM	XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-19-24 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-02-24 07:30AM	XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio (GlobeNewswire)
Nov-11-24 12:00PM	What Makes XOMA Royalty (XOMA) a New Buy Stock (Zacks)
Nov-07-24 09:00AM	XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.96%
07:52AM	XOMA Royalty: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Oct-22-24 08:00AM	XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience (GlobeNewswire)
08:00AM	Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash (Business Wire)
Sep-23-24 06:30AM	Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
05:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-04-24 07:30AM	XOMA Royalty to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 08:45AM	XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.40%
07:39AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Jul-18-24 04:08AM	Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-21-24 07:54AM	Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock? (Zacks) -5.23%
Jun-20-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +15.64%
Jun-12-24 07:30AM	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher (GlobeNewswire)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
May-14-24 07:30AM	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 03:18PM	XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss (GuruFocus.com) +7.39%
May-09-24 01:55PM	XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Xoma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
May-07-24 10:00AM	Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-24 07:30AM	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% (GlobeNewswire)
Apr-25-24 07:30AM	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-03-24 09:00AM	XOMA Corporation Announces Closing of Tender Offer (GlobeNewswire)
Mar-21-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-19-24 04:05PM	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. (GlobeNewswire)
Mar-08-24 12:53PM	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:12AM	XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:52AM	Xoma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Feb-28-24 07:30AM	XOMA to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-16-24 08:00AM	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jan-18-24 08:30AM	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition (GlobeNewswire)
Jan-11-24 04:05PM	FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx (GlobeNewswire)
Jan-08-24 07:30AM	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors (GlobeNewswire)
Jan-02-24 07:30AM	XOMA Announces Stock Repurchase Program of up to $50 Million (GlobeNewswire) +12.92%
Dec-20-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-19-23 07:30AM	XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties (GlobeNewswire) +16.23%
Nov-07-23 07:50AM	Xoma: Q3 Earnings Snapshot (Associated Press Finance) -6.44%
07:30AM	XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Oct-31-23 07:30AM	XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire) +5.66%
Sep-25-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) -6.26%
Sep-06-23 07:30AM	XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:43PM	10 Stocks That Are About To Explode (Insider Monkey)
Aug-13-23 10:07AM	Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA), (Simply Wall St.)
Aug-08-23 08:21AM	Xoma: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy (GlobeNewswire)
Jun-23-23 06:14PM	XOMA Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Jun-22-23 07:30AM	XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset (GlobeNewswire)
Jun-20-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +9.30%
May-16-23 09:29AM	Shareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years ago (Simply Wall St.)

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sitko Bradley	Chief Investment Officer	Sep 19 '25	Option Exercise	0.00	6,712	0	19,822	Sep 23 05:32 PM
Hughes Owen	Chief Executive Officer	Sep 19 '25	Option Exercise	0.00	35,567	0	98,268	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 19 '25	Option Exercise	0.00	11,846	0	34,409	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 22 '25	Sale	35.99	4,330	155,820	30,079	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 19 '25	Option Exercise	0.00	3,033	0	12,134	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 10 '25	Option Exercise	0.00	9,101	0	9,101	Sep 12 04:30 PM
Sitko Bradley	Chief Investment Officer	Jun 30 '25	Buy	25.39	2,000	50,780	7,045	Jul 02 04:30 PM
Hughes Owen	Chief Executive Officer	May 19 '25	Option Exercise	0.00	53,359	0	88,338	May 21 07:11 PM
Hughes Owen	Chief Executive Officer	May 20 '25	Sale	25.38	25,637	650,667	62,701	May 21 07:11 PM
BURNS THOMAS M.	SVP, Finance & CFO	May 19 '25	Option Exercise	0.00	17,773	0	33,045	May 21 07:11 PM
BURNS THOMAS M.	SVP, Finance & CFO	May 20 '25	Sale	25.38	10,482	266,033	22,563	May 21 07:11 PM
BVF PARTNERS L P/IL	10% Owner	May 16 '25	Sale	27.10	392,723	10,642,793	1,267,545	May 20 06:56 PM
Sitko Bradley	Chief Investment Officer	Apr 07 '25	Buy	24.70	2,000	49,400	5,045	Apr 09 04:44 PM
LIMBER JOSEPH M	Director	Apr 03 '25	Buy	25.24	17,935	452,631	16,524	Apr 07 04:39 PM
LIMBER JOSEPH M	Director	Apr 04 '25	Buy	25.40	6,822	173,293	20,000	Apr 07 04:39 PM
LIMBER JOSEPH M	Director	Apr 07 '25	Buy	25.60	5,243	134,221	10,000	Apr 07 04:39 PM
Sitko Bradley	Chief Investment Officer	Mar 31 '25	Buy	21.04	1,245	26,201	11,484	Apr 02 04:30 PM
BURNS THOMAS M.	SVP, Finance & CFO	Apr 01 '25	Buy	25.46	1,000	25,460	2,000	Apr 02 04:30 PM
Sitko Bradley	Chief Investment Officer	Mar 21 '25	Buy	23.89	4,134	98,751	10,484	Mar 25 04:30 PM
BVF PARTNERS L P/IL	10% Owner	Jan 24 '25	Sale	26.10	500,742	13,069,366	0	Jan 28 05:23 PM
BVF PARTNERS L P/IL	10% Owner	Jan 24 '25	Sale	26.10	149,975	3,914,348	0	Jan 28 05:23 PM
Sitko Bradley	Chief Investment Officer	Jan 08 '25	Buy	25.60	313	8,013	313	Jan 10 04:30 PM
Sitko Bradley	Chief Investment Officer	Jan 08 '25	Buy	25.70	232	5,962	82	Jan 10 04:30 PM
Sitko Bradley	Chief Investment Officer	Dec 31 '24	Buy	25.90	300	7,770	9,150	Jan 03 04:30 PM
BURNS THOMAS M.	SVP, Finance & CFO	Nov 11 '24	Option Exercise	0.00	17,773	0	24,328	Nov 13 06:55 PM
BURNS THOMAS M.	SVP, Finance & CFO	Nov 13 '24	Sale	29.94	9,775	292,664	14,553	Nov 13 06:55 PM
Hughes Owen	Chief Executive Officer	Nov 11 '24	Option Exercise	0.00	53,360	0	56,860	Nov 13 06:55 PM
Hughes Owen	Chief Executive Officer	Nov 13 '24	Sale	29.95	21,881	655,336	34,979	Nov 13 06:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XOMA

XOMA Royalty Corp

Upgrade your FINVIZ experience